Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells

A. Falanga, R. Consonni, M. Marchetti, G. Locatelli, E. Garattini, C. Gambacorti Passerini, S. G. Gordon, T. Barbui

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

All-trans-retinoic acid (ATRA) downregulates the expression of two cellular procoagulants, tissue factor (TF) and cancer procoagulant (CPL in human promyelocytic leukemia cella. To evaluate whether or not changes of the procoagulant activities (PCAs) may share mechanisms with the ATRA. induced cyto-differentiation process, we have characterized the effect of ATRA on the TF and CP expression NB4 cells, an ATRA maturation-inducible cell line, end two NB4-derived cell lines resistant to ATRA-induced maturation, the NB4.306 end NB4.007/6 cells. Next, we evaluated the effect on the PCAs of the NB4 parental cells of three synthetic retinoid analogues, ie: AM580 (selective for the retinoic acid receptor [RAR] α), capable to induce the granulocytic differentiation of NB4 cells; and CD2019 (selective for RARβ) end CD437 (selective for RARγ), both lacking this capability. Cells were treated with either ATRA or the analogues (10-6 to 10-8 mol/L) for 96 hours. The effect on cell differentiation was evaluated morphologic changes, cell proliferation, nitro blue tetrazolium reduction assay, and flow cytometry analysis of the CD33 and CD11b surface-antigen expression. PCA was first measured in 20 mmol/L Veronal Buffer cell extracts the one-stage clotting assay of normal and FVII-deficient plasmas. Further TF and CP have been characterized and quantified in cell-sample preparations chromogenic and immunological assays. In the first series of experiments, ATRA downregulates both TF and CP in NB4 parental cells, as expected. However, in the differentiation-resistant cell lines, it induced a significant loss of TF but had little or no effect on CP. In a second series of experiments, in the NB4 parental cells, the RARe agonist (AM580) induced cell maturation and reduced 91% CP expression, whereas CD437 and CD2019 had no cyto-differentiating effects end did not affect CP levels. On the other hand, in the same cells the TF expression was reduced ATRA end AM580, but also the RARβ agonist CD2019, which did not induce cell maturation. These data indicate that in NB4 cells, ATRA modulation of CP occurs in parallel with signs of cell differentiation, while the regulation of TF appears to be at least in part independent from these processes, and involves both α and β nuclear retinoid receptors.

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalBlood
Volume92
Issue number1
Publication statusPublished - Jul 1 1998

Fingerprint

cancer procoagulant
Acute Promyelocytic Leukemia
Thromboplastin
Tretinoin
Retinoic Acid Receptors
Assays
Cell Differentiation
Cells
Retinoids
Cell Line
CD11b Antigens
Down-Regulation
Barbital
Chromogenics
Artificial Cells
Flow cytometry
Cell proliferation
Surface Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Falanga, A., Consonni, R., Marchetti, M., Locatelli, G., Garattini, E., Gambacorti Passerini, C., ... Barbui, T. (1998). Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells. Blood, 92(1), 143-151.

Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells. / Falanga, A.; Consonni, R.; Marchetti, M.; Locatelli, G.; Garattini, E.; Gambacorti Passerini, C.; Gordon, S. G.; Barbui, T.

In: Blood, Vol. 92, No. 1, 01.07.1998, p. 143-151.

Research output: Contribution to journalArticle

Falanga, A, Consonni, R, Marchetti, M, Locatelli, G, Garattini, E, Gambacorti Passerini, C, Gordon, SG & Barbui, T 1998, 'Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells', Blood, vol. 92, no. 1, pp. 143-151.
Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Gambacorti Passerini C et al. Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998 Jul 1;92(1):143-151.
Falanga, A. ; Consonni, R. ; Marchetti, M. ; Locatelli, G. ; Garattini, E. ; Gambacorti Passerini, C. ; Gordon, S. G. ; Barbui, T. / Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells. In: Blood. 1998 ; Vol. 92, No. 1. pp. 143-151.
@article{e0216042d14f41e2a2f118cedea9e54b,
title = "Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells",
abstract = "All-trans-retinoic acid (ATRA) downregulates the expression of two cellular procoagulants, tissue factor (TF) and cancer procoagulant (CPL in human promyelocytic leukemia cella. To evaluate whether or not changes of the procoagulant activities (PCAs) may share mechanisms with the ATRA. induced cyto-differentiation process, we have characterized the effect of ATRA on the TF and CP expression NB4 cells, an ATRA maturation-inducible cell line, end two NB4-derived cell lines resistant to ATRA-induced maturation, the NB4.306 end NB4.007/6 cells. Next, we evaluated the effect on the PCAs of the NB4 parental cells of three synthetic retinoid analogues, ie: AM580 (selective for the retinoic acid receptor [RAR] α), capable to induce the granulocytic differentiation of NB4 cells; and CD2019 (selective for RARβ) end CD437 (selective for RARγ), both lacking this capability. Cells were treated with either ATRA or the analogues (10-6 to 10-8 mol/L) for 96 hours. The effect on cell differentiation was evaluated morphologic changes, cell proliferation, nitro blue tetrazolium reduction assay, and flow cytometry analysis of the CD33 and CD11b surface-antigen expression. PCA was first measured in 20 mmol/L Veronal Buffer cell extracts the one-stage clotting assay of normal and FVII-deficient plasmas. Further TF and CP have been characterized and quantified in cell-sample preparations chromogenic and immunological assays. In the first series of experiments, ATRA downregulates both TF and CP in NB4 parental cells, as expected. However, in the differentiation-resistant cell lines, it induced a significant loss of TF but had little or no effect on CP. In a second series of experiments, in the NB4 parental cells, the RARe agonist (AM580) induced cell maturation and reduced 91{\%} CP expression, whereas CD437 and CD2019 had no cyto-differentiating effects end did not affect CP levels. On the other hand, in the same cells the TF expression was reduced ATRA end AM580, but also the RARβ agonist CD2019, which did not induce cell maturation. These data indicate that in NB4 cells, ATRA modulation of CP occurs in parallel with signs of cell differentiation, while the regulation of TF appears to be at least in part independent from these processes, and involves both α and β nuclear retinoid receptors.",
author = "A. Falanga and R. Consonni and M. Marchetti and G. Locatelli and E. Garattini and {Gambacorti Passerini}, C. and Gordon, {S. G.} and T. Barbui",
year = "1998",
month = "7",
day = "1",
language = "English",
volume = "92",
pages = "143--151",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Cancer procoagulant and tissue factor are differently modulated all- trans-retinoic acid in acute promyelocytic leukemia cells

AU - Falanga, A.

AU - Consonni, R.

AU - Marchetti, M.

AU - Locatelli, G.

AU - Garattini, E.

AU - Gambacorti Passerini, C.

AU - Gordon, S. G.

AU - Barbui, T.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - All-trans-retinoic acid (ATRA) downregulates the expression of two cellular procoagulants, tissue factor (TF) and cancer procoagulant (CPL in human promyelocytic leukemia cella. To evaluate whether or not changes of the procoagulant activities (PCAs) may share mechanisms with the ATRA. induced cyto-differentiation process, we have characterized the effect of ATRA on the TF and CP expression NB4 cells, an ATRA maturation-inducible cell line, end two NB4-derived cell lines resistant to ATRA-induced maturation, the NB4.306 end NB4.007/6 cells. Next, we evaluated the effect on the PCAs of the NB4 parental cells of three synthetic retinoid analogues, ie: AM580 (selective for the retinoic acid receptor [RAR] α), capable to induce the granulocytic differentiation of NB4 cells; and CD2019 (selective for RARβ) end CD437 (selective for RARγ), both lacking this capability. Cells were treated with either ATRA or the analogues (10-6 to 10-8 mol/L) for 96 hours. The effect on cell differentiation was evaluated morphologic changes, cell proliferation, nitro blue tetrazolium reduction assay, and flow cytometry analysis of the CD33 and CD11b surface-antigen expression. PCA was first measured in 20 mmol/L Veronal Buffer cell extracts the one-stage clotting assay of normal and FVII-deficient plasmas. Further TF and CP have been characterized and quantified in cell-sample preparations chromogenic and immunological assays. In the first series of experiments, ATRA downregulates both TF and CP in NB4 parental cells, as expected. However, in the differentiation-resistant cell lines, it induced a significant loss of TF but had little or no effect on CP. In a second series of experiments, in the NB4 parental cells, the RARe agonist (AM580) induced cell maturation and reduced 91% CP expression, whereas CD437 and CD2019 had no cyto-differentiating effects end did not affect CP levels. On the other hand, in the same cells the TF expression was reduced ATRA end AM580, but also the RARβ agonist CD2019, which did not induce cell maturation. These data indicate that in NB4 cells, ATRA modulation of CP occurs in parallel with signs of cell differentiation, while the regulation of TF appears to be at least in part independent from these processes, and involves both α and β nuclear retinoid receptors.

AB - All-trans-retinoic acid (ATRA) downregulates the expression of two cellular procoagulants, tissue factor (TF) and cancer procoagulant (CPL in human promyelocytic leukemia cella. To evaluate whether or not changes of the procoagulant activities (PCAs) may share mechanisms with the ATRA. induced cyto-differentiation process, we have characterized the effect of ATRA on the TF and CP expression NB4 cells, an ATRA maturation-inducible cell line, end two NB4-derived cell lines resistant to ATRA-induced maturation, the NB4.306 end NB4.007/6 cells. Next, we evaluated the effect on the PCAs of the NB4 parental cells of three synthetic retinoid analogues, ie: AM580 (selective for the retinoic acid receptor [RAR] α), capable to induce the granulocytic differentiation of NB4 cells; and CD2019 (selective for RARβ) end CD437 (selective for RARγ), both lacking this capability. Cells were treated with either ATRA or the analogues (10-6 to 10-8 mol/L) for 96 hours. The effect on cell differentiation was evaluated morphologic changes, cell proliferation, nitro blue tetrazolium reduction assay, and flow cytometry analysis of the CD33 and CD11b surface-antigen expression. PCA was first measured in 20 mmol/L Veronal Buffer cell extracts the one-stage clotting assay of normal and FVII-deficient plasmas. Further TF and CP have been characterized and quantified in cell-sample preparations chromogenic and immunological assays. In the first series of experiments, ATRA downregulates both TF and CP in NB4 parental cells, as expected. However, in the differentiation-resistant cell lines, it induced a significant loss of TF but had little or no effect on CP. In a second series of experiments, in the NB4 parental cells, the RARe agonist (AM580) induced cell maturation and reduced 91% CP expression, whereas CD437 and CD2019 had no cyto-differentiating effects end did not affect CP levels. On the other hand, in the same cells the TF expression was reduced ATRA end AM580, but also the RARβ agonist CD2019, which did not induce cell maturation. These data indicate that in NB4 cells, ATRA modulation of CP occurs in parallel with signs of cell differentiation, while the regulation of TF appears to be at least in part independent from these processes, and involves both α and β nuclear retinoid receptors.

UR - http://www.scopus.com/inward/record.url?scp=0032126588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032126588&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 143

EP - 151

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -